Stemirna Therapeutics, a Shanghai RNA biopharma, raised nearly $14 million in a Series A financing. Founded in 2016 by a group of returning PhDs from MD Anderson Cancer Center in Houston, the company uses its proprietary Core Shell Structure Platform for mRNA Vaccines (LPP/mRNA®) to discover new drug candidates. Currently, Stemirna is developing more than a dozen mRNA drug projects that are either mRNA personalized cancer vaccines or vaccines for infectious disease, protein defects or genetic diseases. The company claims to be the first and only platform-based mRNA R&D enterprise in China. Source: China Biotoday
